NUCB2/nesfatin-1 is associated with severity of eating disorder symptoms in female patients with obesity. 2022

Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany; Charité Center for Internal Medicine and Dermatology, Department of Psychosomatic Medicine, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.

Nesfatin-1 has been described as an anorexigenic peptide. Comprehensive evidence also points towards an involvement of nesfatin-1 in the modulation of emotional pathways with a sex-specific regulation of nesfatin-1 in association with anxiety. Although the implication of nesfatin-1 in the regulation of food intake is well-established in animals, data in humans are lacking. Therefore, we investigated a possible association of circulating NUCB2/nesfatin-1 with eating disorder symptoms in female and male patients displaying a wide range of body weight. We enrolled 243 inpatients (177 female, 66 male) hospitalized due to anorexia nervosa (n = 66) or obesity (n = 144) or with normal weight and suffering from somatoform, adjustment, depressive or anxiety disorders (n = 33). Plasma samples (NUCB2/nesfatin-1 levels measured by ELISA) and measures of eating disorder symptoms (by EDI-2, range 0-100) were obtained within three days after admission. The study population displayed a distinct prevalence of eating disorder symptoms with female patients with anorexia nervosa (+ 77.0%, p < 0.001) and obesity (+ 87.9%, p < 0.001) reported significantly higher EDI-2 scores than normal weight patients of the same sex. Accordingly, males with anorexia nervosa (+ 39.7%, p < 0.05) and obesity (+ 51.7%, p < 0.001) had significantly higher EDI-2 scores than males with normal weight. Within the same BMI group, women displayed significantly higher scores than men (+ 21.4%, p < 0.05 in patients with anorexia nervosa, + 18.8%, p < 0.001 in participants with obesity). We observed a positive correlation between NUCB2/nesfatin-1 levels and EDI-2 total scores in female patients with obesity (r = 0.285, p = 0.015), whereas no associations were found in other subgroups. A positive correlation between NUCB2/nesfatin-1 levels and BMI was only observed in the male study population (r = 0.315, p = 0.018). NUCB2/nesfatin-1 plasma levels were positively associated with EDI-2 total scores in women with obesity, while no association was observable in men. The lacking association of NUCB2/nesfatin-1 and EDI-2 total scores in female patients with anorexia nervosa might be due to already low NUCB2/nesfatin-1 plasma levels. Whether NUCB2/nesfatin-1 is selectively involved in eating behavior in women with obesity will have to be further investigated.

UI MeSH Term Description Entries
D008297 Male Males
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D002135 Calcium-Binding Proteins Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS. Calcium Binding Protein,Calcium-Binding Protein,Calcium Binding Proteins,Binding Protein, Calcium,Binding Proteins, Calcium,Protein, Calcium Binding,Protein, Calcium-Binding
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000080866 Nucleobindins A DNA and calcium binding protein which plays a role in calcium homeostasis. CALNUC protein,Nucleobindin,Nucleobindin-1 protein,CALNUC,Nucleobindin 1 protein,protein, CALNUC,protein, Nucleobindin-1
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
November 2013, Psychoneuroendocrinology,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
January 2023, Nutrients,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
January 2015, PloS one,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
January 2013, Current pharmaceutical design,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
January 2013, Current pharmaceutical design,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
January 2013, Current pharmaceutical design,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
April 2018, BMC psychiatry,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
October 2013, Endocrine,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
January 2012, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Elena Weibert, and Tobias Hofmann, and Ulf Elbelt, and Matthias Rose, and Andreas Stengel
December 2016, Current opinion in pharmacology,
Copied contents to your clipboard!